DIAGNOS Announces the Start of the Deployment of its Pathology Detection Systems in the Retail Clinics of Farmacias Benavides, a Member of Walgreens Boots Alliance
June 23 2022 - 9:00AM
DIAGNOS Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce the start of the
deployment of its pathology detection systems in the retail clinics
of Farmacias Benavides, a member of Walgreens Boots Alliance.
“Following the signing of the agreement between
DIAGNOS and Farmacias Benavides we announced in May, the hard work
carried out by our team in Mexico has paid off as it already
permitted the training of 30 doctors and the successful completion
of the first series of deployments of our pathology detection
systems in 7 retail clinics”, said Mr. Guillermo Moreno
Robles, VP of DIAGNOS. “As we continue to work with
Farmacias Benavides on the deployment of our systems throughout
their network of over 1,100 drugstores, the initial results make us
confident that the recurring and continuously growing stream of
revenue generated in this sector will yield strong financial
benefits to our respective organizations”, Mr. Moreno
Robles concluded.
As part of its commitment to helping families
improve their quality of life, and in line with its market share
growth strategy, Farmacias Benavides has taken a leadership
position in the area of retail clinics by increasing at a rapid
rate the number of its locations where doctors provide medical
consultations. As such, the Mexican population is now able to
access first-class medical care, directly at their local community
pharmacy, with real doctors.
The blossoming of retail clinics was boosted by
the pandemic and by a bill enacted by the Mexican health
authorities that favored the opening of retail clinics. According
to COFEPRIS, the government Commission responsible for regulating
health related topics in Mexico, more than 10.6 million Mexicans
now enjoy the benefits from this new ambulatory care environment
each month.
Mr. André Larente, President of
DIAGNOS mentioned, "The favorable conditions of the
Mexican market and the fact that our pathology screening services
are directly integrated into the chronic disease management
programs offered by Farmacias Benavides, contribute to our
deployment and will allow a significant increase in the popularity
of our services, while raising awareness about to the significant
decline in quality of life at risk of occurring when annual eye
exams are not conducted. In addition, since we deploy our services
in numerous retail locations, each open from 8 a.m. to 10 p.m.,
seven days a week, our pathology screening services will now
benefit from one of the greatest possible market accessibility in
the world.”
About Farmacias BenavidesFarmacias Benavides is
the market leader in retail sales of health and wellness products
in Mexico. With 104 years of experience, they have a presence in
more than 197 cities in 24 states. They own a network of more than
1,100 pharmacies, more than 400 medical offices and a high-tech
distribution center. The chain is operated by more than 8,000
collaborators offering a catalog of more than 16,000 different
products of commercial and own brands focused on helping the health
and well-being of its customers.
Additional information is available at:
www.benavides.com.mx/
About Walgreens Boots Alliance (WBA)Walgreens
Boots Alliance is an integrated healthcare, pharmacy and retail
leader serving millions of customers and patients every day, with a
170-year heritage of caring for communities. With approximately
13,000 locations across the U.S., Europe and Latin America, WBA
plays a critical role in the healthcare ecosystem. Through
dispensing medicines, improving access to a wide range of health
services, providing high quality health and beauty products and
offering anytime, anywhere convenience across its digital
platforms, WBA is shaping the future of healthcare.
Additional information is available:
www.walgreensbootsalliance.com/investors
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
Email: alarente@diagnos.com
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024